Background: Normal serum alanine aminotransferase (ALT) levels differ with age, gender, and body mass index. Adjusting the upper limits of normal (ULN) for ALT needs further research in different populations. Aim of this work was to monitor the effect of successful chronic hepatitis C (CHC) treatment on the ALT levels in patients with normal pretreatment ALT.
where the interferon was the mainstay therapy, rapid normalization of ALT was used together with rapid virological response (RVR), as predictors for treatment outcomes, 26 current practice guidelines for managing HCV, do not consider liver enzymes as a prerequisite for treatment, but still use them as markers of hepatic cell injury. 27 We aim at studying changes in ALT levels during and after treatment of chronic HCV patients using DAAs in a group of patients with baseline enzymes falling below the current upper limit of normal according to currently used cutoff values, and try to explore whether a new upper limit of normal for ALT is to be considered in HCV patients based on the decline in ALT values in those patients as a response to successful treatment.
| PATIENTS AND METHODS
In January 2017, data of treatment naïve CHC patients (n=1160) and September 2016. Pretreatment sociodemographic and clinical data (gender, age, weight, height, body mass index, and treatment status), laboratory investigations done before treatment (hemoglobin, white blood cell count, platelets count, ALT, AST, HCV viral load, blood glucose, albumin, and total bilirubin), and abdominal ultrasound in addition to assessment of hepatic fibrosis using FIB-4 score were collected. Patients with other types of chronic liver diseases, Child-Turcotte-Pugh class B or C, or receiving any concomitant drugs were excluded. ALT levels were followed up during treatment and at time of assessing SVR (12 weeks after treatment cessation). Treatment response to antiviral therapy (interferon and non-interferon containing) was recorded. ALT level changes were monitored during and after therapy in all patients and were analyzed in correlation with other demographic, laboratory, and radiologic characteristics.
| Statistical analysis
To maintain confidentiality; participants were assigned serial identification numbers. Descriptive analysis of liver enzymes and other variables at baseline was conducted. The 2.5th, 5th, 10th, 15th, 20th, 25th, 50th (median), 75th, 95th, and 97.5th percentiles were calculated for ALT and AST levels at baseline-the percentiles of interest are at the lowest ranges. As the normal mean value of ALT is higher in males than in females, this was further stratified by gender.
Univariate analyses including the Student's t test were used to
compare the baseline levels of ALT and AST with continuous variables.
The chi-square test was used to examine the association of baseline ALT and AST with categorical variables.
The effect of treatment on change in ALT and AST levels from baseline to during and after treatment was analyzed using multivariate analysis by a general linear model for repeated measurements with correction for sphericity.
To explore for a possible new cutoff for ALT, we used the proposed new definitions for ULN enzymes as suggested by Prati et al. 
| RESULTS
Our study included 1160 CHC patients with liver enzymes falling within the normal laboratory range (≤40 IU/L). They were 568 males (49%) and 592 females (51%) with mean age of 50.7 years. General characteristics of the studied patients are presented in Table 1 . Mean values of ALT and AST at baseline (before treatment) were significantly higher in males than females. They were also significantly higher in patients with cirrhosis or treatment experience. Obesity had no effect on ALT and AST at baseline (Table S1 ). The percentiles of ALT and AST at baseline are presented by gender in Table 2 . Although ALT and AST levels decreased with treatment, there was only significant effect of treatment regimen and treatment response on enzyme lowering. Patients treated with interferon-free regimens had more significant lowering of liver enzymes than those treated with interferon containing regimens. Also, patients who achieved sustained virologic response (SVR) had more significant lowering of liver enzymes than those who did not respond to treatment (Table S2) vs interferon free) had no significant effect on ALT lowering during antiviral therapy (Table 3) . Applying a new cutoff for upper limit of normal (30 IU/L) for males showed that 88.8% of patients had ALT level falling below the new cutoffs after treatment (Table 4 ). In females, the used new cutoff for upper limit of normal (19 IU/L) showed that 59% of patients had ALT level falling below the new cutoffs after treatment (Table 3) .
Receiver operating characteristic (ROC) curves analyses suggested a 
| DISCUSSION
Liver enzymes are considered biomarkers of hepatocellular injury 28 and in the majority of patients with CHC, serum levels reflects the degree of hepatocellular damage, although many people with significant liver damage show persistently serum ALT levels. Accordingly, different factors affecting the integrity of hepatocytes are supposed to affect the level of the liver enzymes. Although persistently elevated ALT for more than 6 months is used as a criterion for diagnosing chronic hepatitis, 29 who found that ALT and AST levels were significantly higher in male than females with or without hyperbilirubinemia and by different epidemiological studies showing that male gender have a higher risk of elevated ALT. 32 However, this is in controversy to the results of a study published at 2014 by Bakht and Grace which found that females showed higher liver enzymes than males. 33 Although ALT is supposed to be very specific to liver disease and is related to liver fat accumulation, 34 obesity as a factor showed no statistical significance on the level of ALT. This was different from a study carried by Shuang Chen and his colleagues 35 who found that ALT level elevation was independently associated with metabolic syndrome. The same study did show a significant elevation in the level of AST with obesity but not as strong as in ALT. In our study; cirrhosis correlated significantly in an inverse manner with the ALT level. This lies in concordance with a previously published study which observed that advanced fibrosis was accompanied by persistently normal ALT.
33
That is why liver biopsy was considered for some time as a mean for judging the eligibility of treatment in HCV patients with normal liver enzymes. 36 In our study, we found that patients treated with interferon-free regimens had more significant lowering of liver enzymes than those treated with interferon containing regimens. This may be explained by the fact that interferon exerts a more complex actions (antiangiogenic, antifibrotic, and immunomodulating), on the host rather than on the virus, while DAAs have only direct antiviral action. There was statistically significant decrease in the mean of ALT levels after treatment in treatment naïve patients than experienced patients. Also, the mean ALT decreased significantly after treatment in responders than non-responders. This statistical significance was not found when comparing ALT values at baseline, Limitations of our study include:
Despite being a retrospective data analysis study, the large number of the studied population could add to the reliability of results.
Our results and cutoff values should be carefully interpreted. We have studied chronic HCV patients only, so our results may not be applicable in other chronic liver diseases. We did not have baseline liver histology before treatment, so careful interpretation should be done also in patients with cirrhosis. Lack of a healthy population cohort to be used as a control group makes these results only exploratory and prospective studies in different chronic liver diseases with healthy control arm is needed to confirm our results.
Our study has many points of strength. First, it is done on large number of patients which makes the results more realistic. Second, various treatment regimens for HCV were used including interferon and non-interferon-based therapies, which added strength to our results as many regimens did not affect our hypothesis of new cutoff values for liver enzymes.
| CONCLUSION
The current upper limit of normal for ALT needs readjustment to best identify normal cutoffs in CHC patients after SVR. Posttreatment cutoffs for ALT differ according to gender, pretreatment stage of liver disease, and treatment regimen. 
